The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline. This story matters for Finance & Markets readers tracking option. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. OptionNews curates and briefs the finance & markets stories that matter. Our editorial policy →